FisherVista

An analysis reveals that top-performing semiconductor stocks are those providing bottleneck products for the AI boom, indicating shifting investor interest.

Major crypto exchanges are urging lawmakers to delete language targeting risky tokens from the Clarity Act, a move that could reshape digital asset regulation in the U.S.

Growing demand for artificial intelligence drove gains across cloud, chip, and cable stocks on Thursday, signaling that AI investment is expanding beyond graphics processors into broader digital infrastructure.

Titan Partners Group LLC has appointed three senior analysts with over 40 years of combined experience to expand its equity research coverage in technology, healthcare, and energy sectors, strengthening its investment banking services for small- and mid-cap public companies.

The NHS in England is offering a new one-minute injection of pembrolizumab, replacing hour-long infusions, significantly reducing administration time for thousands of cancer patients.

OS Therapies Inc. (NYSE: OSTX) has achieved significant regulatory clarity for its lead candidate OST-HER2, with EMA rolling review initiation and TGA endpoint alignment, positioning the company for a dense 2026 catalyst calendar that includes pivotal survival data and potential EMA approval.

AI Maverick Intel issued 76.5 million shares as initial consideration for its proposed acquisition of HEAL Access Canada, reducing total consideration to 100 million shares, and plans to uplist to OTCQB.

Nevada Organic Phosphate Inc. has started drilling on its 2026 exploration program at the Murdock Mountain Project, targeting the Meade Peak Upper Phosphatic Zone to evaluate thickness and grade, with minor technical issues being addressed.

LaFleur Minerals announced wide gold intercepts from drilling at the Swanson Gold Project, confirming mineralization continuity and supporting expansion potential beyond current resource models.

Bullish (NYSE: BLSH) has agreed to acquire Equiniti for $4.2 billion, combining its digital asset platform with Equiniti's regulated transfer agent services to create a global platform for tokenized securities.

SPARC AI Inc. has been featured in an AINewsWire editorial highlighting the critical role of software-driven autonomy in drone warfare, particularly its GPS-denied navigation and targeting capabilities.

Lunai Bioworks has filed a federal securities fraud lawsuit in Delaware, accusing unidentified naked short sellers of violating SEC regulations through excessive failures to deliver shares, including trades exceeding the company's outstanding shares by over 15 times.

MindBio Therapeutics is advancing an AI-driven voice analysis platform to detect real-time drug and alcohol impairment, with potential impacts on law enforcement, workplace safety, and healthcare.

Oncotelic Therapeutics' proprietary intranasal delivery platform is featured in a BioMedWire editorial, emphasizing its potential to overcome the blood-brain barrier for CNS treatments and biodefense.

SPARC AI Inc. was featured in an AINewsWire editorial examining how software-driven autonomy is transforming drone warfare, highlighting the company’s AI platform that enables GPS-denied navigation and targeting without additional hardware.

Stonegate Capital Partners updates coverage on Viemed Healthcare, highlighting improved free cash flow conversion and a shift in revenue mix away from legacy ventilation toward sleep, resupply, and maternal health.

MindBio Therapeutics CEO Justin Hanka appeared on the TechMediaWire Podcast to discuss the company's AI-driven voice analysis technology for detecting drug and alcohol intoxication, with a focus on improving safety in regulated workplaces like mining.

SureNano Science Ltd. is highlighted in a BioMedWire editorial for its subsidiary GlucaPharm's GEP-44 program, a novel triple agonist peptide that aims to improve efficacy, tolerability, and delivery flexibility in the growing GLP-1 market for obesity and metabolic disease treatment.

Tonix Pharmaceuticals highlighted commercial progress for its newly launched fibromyalgia treatment TONMYA, including a managed care agreement covering up to 35 million lives, and announced positive Phase 1 data for a Lyme disease prevention candidate, TNX-4800.

Lantern Pharma will report its Q1 2026 results on May 15, highlighting progress in AI-driven oncology trials and the commercial launch of its withZeta.ai platform.